TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03787251
Drug: The chemotherapeutic drug chosen by the investigator.
Approvals — FDA: no, EMA: no, PMDA: no
Description: The choice of chemotherapy regimen is based on the medication habits of the drug delivery doctor and the specific circumstances of the patient.~In addition, the following regimens may be selected as monotherapy or combination: docetaxel 60-75 mg/m2d1 q3w; irinotecan 150-180 mg/m2 d1 q2w until disease progression or patient death. If grade 3 and above or non-hematologic toxicity of grade II and above adverse event appeared, allowing the dose to be lowered twice.
Study: NCT01453634
Drug: Lunacalcipol 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 subjects are planned to receive a total of 11 doses of the study drug given three times per week (tiw) over 24 days (day 1 to day 24), administered not more often than every other day.
Study: NCT01453634
Drug: Lunicalcipol 270
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 subjects are planned to receive a total of 11 doses of the study drug given three times per week (tiw) over 24 days (day 1 to day 24), administered not more often than every other day.
Study: NCT01287897
Drug: PF-04236921 SC injection
Normalized name: taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo delivered SC, 2 doses separated by 4 weeks
Study: NCT01287897
Drug: PF-04236921 SC injection
Normalized name: taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug dose level 1 delivered SC, 2 doses separated by 4 weeks
Study: NCT01287897
Drug: PF-04236921 SC injection
Normalized name: taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug dose level 2 delivered SC, 2 doses separated by 4 weeks
Study: NCT00249444
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01499667
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo in capsules for oral administration once daily.
Study: NCT02673489
Drug: SOF
Normalized name: Kasof
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01918904
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A small amount of topical zinc oxide and aquaphor cream twice daily (bid)
Study: NCT01300780
Drug: Etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 - experimental Etoricoxib will receive two doses of selective anti-inflammatory to enzyme cyclooxygenase 2 (COX-2) (Etoricoxib 60 mg) given once every 24 hours;
Study: NCT03041935
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm description
Study: NCT01758094
Drug: Sustanon 250 mg ampule (Testosterone esters)
Normalized name: testosterone enanthate 250 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug used for treatment of hypogonadism
Study: NCT01897532
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo matching tablets
Study: NCT01627886
Drug: Ibandronate sodium
Normalized name: Ibandronate Sodium
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate sodium Tablets 150 mg
Study: NCT03646357
Drug: Betablocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: A betablocker will be administered. To reflect contemporary management, for which this study is designed to test, there will not be a defined minimum dosage. The type and dose of BB will be left at the discretion of the PI. Generic drug and accepted dosages will be:~* Metoprolol succinate up to a total dose of 200mg daily~* Bisoprolol up to a total dose of 10mg daily~* Carvedilol up to a total dose of 50mg daily~The treating physician will be encouraged to aim for an equipotent dose of 100 mg metoprolol succinate or higher. Any other treatment or management is to be given as per usual care.
Study: NCT03721822
Drug: [18F]NOS
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]NOS is an investigational radiotracer which each subject will have one \[18F\]NOS positron emission tomography/computed tomography (PET/CT) scan performed.
Study: NCT03538743
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 0 mg, twice daily, 28 days
Study: NCT01978483
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04470388
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match EDP-514
Study: NCT03728933
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: not applicable
Study: NCT01317992
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 4 capsules, orally, twice daily for 8 weeks.
Study: NCT00582907
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo by subcutaneous injection weekly for 3 months
Study: NCT02403544
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine: by oral, D1-14, every 21 days, 600mg/m2 bid per day in level 1, and then escalated every another dose level.
Study: NCT00186628
Drug: Mycophenylate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenylate mofetil (MMF) will be administered at 15 mg/kg po Day 0, at 5 to 10 hours after mobilized PBPC infusion is complete
Study: NCT00186628
Drug: Solumedrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solumedrol, an anti-inflammatory glucocorticoid containing methylprednisolone sodium succinate, administered at 1 mg/kg as a premedication for anti-thymoglobulin (ATG)
Study: NCT00186628
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen administered orally at 650 mg 1 hour prior to infusion of PBPC
Study: NCT00186628
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone administered by intravenous infusion at 100 mg 1 hour prior to infusion of PBPC
Study: NCT00089622
Drug: Intravenous Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02125344
Drug: non-pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/m2, i.V. 18 times weekly
Study: NCT02125344
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2000 mg/m² every 2 weeks for 3 cycles.
Study: NCT02923154
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04344730
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Box of 10 NaCl 0,9% , solution for injection in ampoule of 5mL. Each allocated box contains complete treatment from D1 to D10 for one patient.
Study: NCT03383042
Drug: Cohort 1 (JP-1366 A mg)
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [JP P Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: JP-1366 A mg or JP-1366 Placebo or Esomeprazole 40 mg
Study: NCT03383042
Drug: Cohort 3 (JP-1366 C mg)
Normalized name: FD & C RED #3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: JP-1366 C mg or JP-1366 Placebo or Esomeprazole 40 mg
Study: NCT03383042
Drug: Cohort 6 (JP-1366 F mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: JP-1366 F mg or JP-1366 Placebo or Esomeprazole 40 mg
Study: NCT03383042
Drug: Cohort 7 (JP-1366 G mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: JP-1366 G mg or JP-1366 Placebo or Esomeprazole 40 mg
Study: NCT03383042
Drug: Cohort 8 (JP-1366 H mg)
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [JP P Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: JP-1366 H mg or JP-1366 Placebo or Esomeprazole 40 mg
Study: NCT01130337
Drug: Capecitabine [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.000 mg/m2 orally every 12 hours from day 1 to day 14 of every cycle for 6 cycles
Study: NCT03901638
Drug: Tllsh2910
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tllsh2910 80mg twice per day orally for 12 weeks
Study: NCT03901638
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03553537
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750mg/m² iv on day 6
Study: NCT03553537
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DOX
Study: NCT03101319
Drug: B Complex Oral Tablet
Normalized name: vitamin B complex Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: As mentioned in the description of the study arm
Study: NCT02049411
Drug: physiological solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: physiological solution at 0.9% (250 ml) during 2 hours, intravenously, with the same physical characteristics of ketamine.
Study: NCT00929214
Drug: Standard Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and/or Endocrine Therapy:~For 3 - 9 months, all patients will receive systemic chemotherapy agents appropriate for the tumor characteristics and patient's prior treatment history, and may also be placed on endocrine therapy as determined by the treating medical oncologist.
Study: NCT00730054
Drug: Remifentanil+clonidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv Remifentanil+ iv clonidine
Study: NCT03971929
Drug: SHR0532
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily(QD) for 4weeks
Study: NCT03971929
Drug: SHR placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily(QD) for 4weeks
Study: NCT00541112
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00541112
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00541112
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02412670
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02412670
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02916316
Drug: R-CHOP with doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoimmunotherapy every 21 days for 6 cycles. In unfavourable patients (stage II-IV) are allowed 2 additional cycles of rituximab at the end of the 6 cycles of R-CHOP.
Study: NCT00565409
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week).
Study: NCT00565409
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC), once weekly from week 36 to week 88.
Study: NCT01425476
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
Study: NCT01425476
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
Study: NCT02832570
Drug: Placebo, Oral intake single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)
Study: NCT00654537
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00654537
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00654537
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02249403
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02325063
Drug: Corticoid injection
Normalized name: Corticool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with an injection of Corticoids.
Study: NCT01726374
Drug: BEP(500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One cycle of BEP(500):~Etoposide 165 mg/m2 IV infusion - days 1, 2, 3 Cisplatin 50 mg/m2 IV infusion - days 1, 2 Bleomycin 30,000 IU IV infusion - days 1 (or 2), 8, 15
Study: NCT04153487
Drug: Ascorbic Acid Injectable Product
Normalized name: ascorbic acid Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Intravenous Infusion of Ascorbic Acid (Vitamin C) 2.5 gm / 6 hours for 96 hours
Study: NCT04153487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo saline / 6 hours for 96 hours
Study: NCT00265850
Drug: FOLFOX or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive oxaliplatin 85 mg/m\^2 IV infused over two hours followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus, then 2400 mg/m\^2 continuous IV infusion over 46-48 hours
Study: NCT00265850
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive irinotecan 180 mg/m\^2 IV infused over 90 minutes followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus following leucovorin then 2400 mg/m\^2 continuous IV infusion over 46-48 hours.
Study: NCT04031729
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical, blinded placebo tablets will be given once daily, for the duration of the clinical trial.
Study: NCT03961126
Drug: Injection of autologous fatty tissue associated with autologous platelet-rich plasma.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 2 separate infiltrations for three months by intra and subdermal injection of autologous fatty tissue (20cc) associated with autologous platelet-rich plasma (4cc) in each half vulvar.
Study: NCT03961126
Drug: Corticosteroids (clobetasol 0.05%)
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a maintenance treatment of topical therapy with corticosteroids (clobetasol 0.05%) that will be administered by usual clinical practice.
Study: NCT00332696
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic saline solution
Study: NCT00114491
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00382174
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of 0.00% thymosin beta 4 qd up to 84 days
Study: NCT00961038
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), placebo will be given twice daily, with a concluding single dose (on day 12)
Study: NCT01470157
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline (placebo) in addition to Midazolam 0.5mg/kg as oral suspension
Study: NCT01306292
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is normal saline 0.9% for injection used as the comparator administered at 4.8 mL (same dose as SonoVue)
Study: NCT00353002
Drug: Maxilene (4% Liposomal Lidocaine)
Normalized name: Maxiclens
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02814656
Drug: AZD8871
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple inhaled doses of AZD8871 will be administered via single dose dry powder inhaler (DPI). Each subject will receive a single inhaled dose of AZD8871 on Day 1 and then single once daily inhalations of AZD8871 will be administered for 12 days from Day 5 until Day 16.
Study: NCT02814656
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple inhaled doses of placebo powder will be administered via single dose DPI. Each subject will receive a single inhaled dose of placebo on Day 1 and then single once daily inhalations of placebo will be administered for 12 days from Day 5 until Day 16.
Study: NCT01464879
Drug: Testosterone Gel (FE 999303)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02563782
Drug: tacrolimus and mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Immunosuppressive Agents
Study: NCT02563782
Drug: Placebo tacrolimus and mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: placebo
Study: NCT01228214
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 5mg/daily for 12 months
Study: NCT01228214
Drug: amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg/daily for 12 months
Study: NCT03807583
Drug: Aminoven 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: After randomization to the visit Day 60, two months after patients inclusion (Visit Day 0) and one month after clinical examination (Visit Day 30), patients will be assigned to a group:~* group A: RENORAL® product~* group B: AMINOVEN® 10% product~* group C: control group (without intradialytic supplementation)~Patients will consume the products and will be followed for 3 months, one visit per month (Day 90, Day 120, Day 150). Protocol visits are included in the patient's course of care.
Study: NCT01455480
Drug: RPh201, botanical drug product
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical
Study: NCT01193101
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696
Study: NCT01193101
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo to LCZ696
Study: NCT02347085
Drug: Placebo MDI
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01192880
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive bitopertin matching placebo once daily for 56 weeks.
Study: NCT01192880
Drug: Antipsychotics
Normalized name: ANTIPSYCHOTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will continue to receive their stable antipsychotic regiment throughout the study. Study protocol does not specify any particular antipsychotic drug and regimen.
Study: NCT02834819
Drug: 3% Nebulized Hypertonic Saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03959293
Drug: FOLFIRI Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Irinotecan: 180 mg/m² by 2-hour IV infusion,~* Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2-hours IV infusion,~* 5-FU bolus: 400 mg/m² by 10-minutes IV bolus,~* Continuous 5-FU: 2400 mg/m² by 46-hour IV infusion
Study: NCT00363584
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01465009
Drug: Acetylsalicylic acid (Aspirin, BAYE4465)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single Administration of 2 tablets Acetylsalicylic acid (500 mg each); in addition, 2 tablets matching placebo to Paracetamol
Study: NCT01465009
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Administration of 2 tablets matching Placebo to Acetylsalicylic Acid together with 2 tablets matching placebo to Paracetamol
Study: NCT01240863
Drug: Hydrocodone ER
Normalized name: hydrocodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.~Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.~Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.
Study: NCT01240863
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching the active drug dose identified during the titration period was taken by participants randomized to the placebo treatment arm during the double-blind treatment period.~Participants were instructed to take intervention with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.
Study: NCT01730872
Drug: Prednisolone Sodium Phosphate Ophthalmic Solution 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop in each eye, four times/day for 4 days.
Study: NCT01730872
Drug: Tears Naturale II Ophthalmic Solution
Normalized name: Tears Naturale Ophthalmic Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: one drop in each eye, four times/ day (QID) for 4 days
Study: NCT00298636
Drug: adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03768427
Drug: Placebo for FDC EZ/Ator
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single placebo tablet administered orally QD for 84 days
Study: NCT01644643
Drug: Best Available Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to receive Best Available Therapy will receive the best available standard of care (SOC) anti-infective therapy for their infection administered in accord with approved local label recommendation
Study: NCT02756403
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg
Study: NCT02756403
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg
Study: NCT02756403
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills will be given before the uterine aspiration. Antibiotics will be given after the uterine aspiration.
Study: NCT00613431
Drug: CS8080
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-8080 tablets will be administered once daily at doses of 1, 3, 10, 20, 50 and 100 mg.